PROPOFOL INDUCTION
Four cases have been reported to S.C.I.D.v.A. (Table 1) in which an induction dose of propofol precipitated death from cardiovascular collapse in higher risk (ASA physical status Ill-V) patients in N.S.W. in 1990 and 1991. No death following a bolus dose of propofol was identified in better-risk patients. It may be that some anaesthetists are unaware of the manufacturer's recommendation that an induction dose of propofol should be given by slow titration (20 mg per 10 seconds) against clinical signs in ASA Ill-IV patients 3 • This recommendation quotes reports of 1.0 mg/kg being a satisfactory induction dose in these patients·· 5 • The minimum induction dose is strongly influenced by factors such as serum albumin concentration as well as age, ASA physical status and rate of administration 6 • Peacock et al (1992)1 found that a bolus dose of 0.82 mg/kg was sufficient for successful induction in elderly (> 60 years age) ASA I and II patients.
Cardiovascular depression following propofol is greater than that caused by comparable doses of thiopentone& particularly in the presence of coronary artery disease 9 • The blood pressure decreases after propofol induction may remain low despite the stimulus of intubation in both fit'O and geriatric" patients.
The rapid clearance of pro pofo I in poor-risk patients is not a clinically significant issue when compared with the risks of profound cardiovascular depression. Certainly in none of the cases reported here was a rapid awakening to produce early "street-fitness" a consideration in drug selection. Currently in Australia there is no short-acting agent available for the induction of general anaesthesia in the poor and desperate risk patient that is in itself free of an additional risk. Particular risks of the commonly used induction agents thiopentone and propofollie in cardiovascular depression and possible irreversible cardiac decompensation in the severely compromised patient. Ketamine has a place but relies on sympathetic stimulation to minimize cardiovascular depression" and such a response may be absent in severely ill patients. Agents such as fentanyl and midazolam in appropriate doses may be more safely used as induction and maintenance agents for longer procedures I3 . 1 s, but are in no way short-acting.
Etomidate is both short-acting and has minimal cardiovascular effects in the fitl6 and in the poor-risk patient I7
• I '. Etomidate was the only induction agent that did not decrease blood pressure in patients for elective cardioversion l9 or other haemodynamic parameters in patients with impaired cardiac function 20 • However, it has been reported in other studies ll . 2l as causing reductions in cardiovascular parameters similar to propofol.
Etomidate is available for use as an intravenous induction anaesthetic in the U.K. and U.s.A., but has not been released for use in Australia. There is a reduction in cortisol response to trauma in patients receiving etomidate by intravenous infusion for sedation over periods of many days in intensive care 2 >. This observation has little relevance to the use of the drug as a single-dose induction agent, where the cortisol suppression is likely to be beneficial intraoperatively and has a time course of one to two hours, in keeping with the rapid clearance of the drug from the body23. Induction doses of thiopentone also inhibit ACTH-stimulated production of cortisol, but to a lesser extent than etomidate 24 .
Given the limitations of drugs currently available for induction of anaesthesia in the high-risk patient, anaesthetists must remain mindful of the special need for incremental administration of induction agents titrated with caution against clinical signs and not associate rapid recovery with freedom from cardiovascular depression.
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